MX2022011518A - Metodos para tratar deambulacion asociada a proteinopatia. - Google Patents
Metodos para tratar deambulacion asociada a proteinopatia.Info
- Publication number
- MX2022011518A MX2022011518A MX2022011518A MX2022011518A MX2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A
- Authority
- MX
- Mexico
- Prior art keywords
- proteinopathy
- wandering
- patients
- treating
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003590 rho kinase inhibitor Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 230000007425 progressive decline Effects 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994527P | 2020-03-25 | 2020-03-25 | |
| US202063005913P | 2020-04-06 | 2020-04-06 | |
| PCT/US2021/012587 WO2021194608A1 (en) | 2020-03-25 | 2021-01-08 | Methods of treating proteinopathy- associated wandering |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011518A true MX2022011518A (es) | 2022-10-07 |
Family
ID=77855102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011518A MX2022011518A (es) | 2020-03-25 | 2021-01-08 | Metodos para tratar deambulacion asociada a proteinopatia. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11642352B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4125879A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023518707A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115916187A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3170073A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022011518A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021194608A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US12329761B2 (en) | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| EP4181925A4 (en) * | 2020-07-14 | 2024-07-31 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PROTEINOPATHIES |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3236338A1 (en) * | 2021-11-12 | 2023-05-19 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis and dosing regimen for same |
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| MX2024009983A (es) * | 2022-02-17 | 2024-08-26 | Woolsey Pharmaceuticals Inc | Formulaciones orales de fasudil que enmascaran el sabor. |
| MX2024010030A (es) * | 2022-02-17 | 2024-09-24 | Woolsey Pharmaceuticals Inc | Formulaciones orales de fasudil con resina de intercambio ionico. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| WO2000009133A1 (fr) * | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil |
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| US20090318485A1 (en) * | 2006-07-20 | 2009-12-24 | Kalypsys, Inc. | Novel inhibitors of rho kinase |
| EP2061314A4 (en) | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20080044390A1 (en) | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
| US20110237600A1 (en) | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| CN101612157A (zh) | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| EP2825175B1 (en) | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017195224A1 (en) | 2016-05-09 | 2017-11-16 | Istituto Superiore Di Sanita' | Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| EP4181925A4 (en) * | 2020-07-14 | 2024-07-31 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PROTEINOPATHIES |
-
2021
- 2021-01-08 US US17/144,802 patent/US11642352B2/en active Active
- 2021-01-08 CA CA3170073A patent/CA3170073A1/en active Pending
- 2021-01-08 WO PCT/US2021/012587 patent/WO2021194608A1/en not_active Ceased
- 2021-01-08 CN CN202180036165.2A patent/CN115916187A/zh active Pending
- 2021-01-08 EP EP21776897.7A patent/EP4125879A4/en not_active Withdrawn
- 2021-01-08 JP JP2022554548A patent/JP2023518707A/ja active Pending
- 2021-01-08 MX MX2022011518A patent/MX2022011518A/es unknown
-
2023
- 2023-03-24 US US18/189,478 patent/US20230226073A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN115916187A (zh) | 2023-04-04 |
| CA3170073A1 (en) | 2021-09-30 |
| US11642352B2 (en) | 2023-05-09 |
| US20210299140A1 (en) | 2021-09-30 |
| US20230226073A1 (en) | 2023-07-20 |
| EP4125879A4 (en) | 2024-04-03 |
| JP2023518707A (ja) | 2023-05-08 |
| EP4125879A1 (en) | 2023-02-08 |
| WO2021194608A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430751B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| SA521430753B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| MX2026000122A (es) | Inhibidores de kcnt1 y metodos de uso | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| NO961326L (no) | Inhibitorer av -amyloidproteinproduksjon | |
| NZ765495A (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer’s disease | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| MX2020013115A (es) | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| ZA202210560B (en) | Inhibiting creb binding protein (cbp) | |
| WO2021252895A3 (en) | Compositions and methods for the treatment and prevention of neurological disorders | |
| MX2023000360A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| MX2022010625A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| MX2020014203A (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurológicos. | |
| MX2021006985A (es) | Metodos para el tratamiento de la depresión. | |
| BR112023020900A2 (pt) | Compostos tetracíclicos para tratamento de distúrbios cerebrais | |
| WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
| WO2022140547A3 (en) | Kcnt1 inhibitors and methods of use | |
| GEP20247644B (en) | Inhibitors of adrenoreceptor adrac2 | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| JP2017524143A5 (cg-RX-API-DMAC10.html) | ||
| WO2023107723A3 (en) | Cyclic compounds and their use for the treatment of neurological disorders |